Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

ClinicalTrials.gov ID

NCT06141070

Lead Sponsor

Vastra Gotaland RegionOTHER_GOV

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

240Estimated

Last Update Posted

Apr 14, 2026Actual

Start Date

Dec 1, 2023Actual

Primary Completion Date

Dec 1, 2028Estimated

Completion Date

Dec 1, 2028Estimated

Official Title

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease - An Open Label Randomized Phase III Trial Comparing Up-front Radiation in Oligometastatic Non-small Cell Lung Cancer (NSCLC) and Systemic Treatment With Systemic Treatment Alone

Brief Summary

This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC. Stratification factors: performance status, gender and systemic strategy. The systemic treatment consists of chemotherapy/chemoimmunotherapy or immunotherapy and is given according to local practice. During the first 3 months of systemic treatment, aiming to start around the 2nd cycle is radiotherapy delivered to all known lesions. Preferably with SBRT /SRT/SRS but conventional radiotherapy may also be used. After the first three cycles of systemic treatment, the patients are assessed, and after four cycles, they are continuing maintenance therapy if indicated. The patients are followed with radiology every three months.

• Non Small Cell Lung Cancer

• Standard systemic therapy + radiotherapy
• Standard systemic therapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening procedures

  • Histological or cytological diagnosis of NSCLC

  • Stage IV disease with ≤5 metastases (not including primary tumour or mediastinal nodes, N1-N3)

  • Patient deemed fit for first line chemoimmunotherapy, immunotherapy or chemotherapy

  • Extra-thoracic metastases accessible for stereotactic body radiotherapy (SBRT)

  • Thoracic tumour(s) accessible for SBRT or conventional radiotherapy

  • Received no prior systemic treatment or radiation therapy for NSCLC (previous adjuvant systemic therapy is allowed)

  • Age > 18 years at time of study entry, no upper age limit

  • WHO performance status 0-2

  • Adequate normal organ and marrow function Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects.

    • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Exclusion Criteria:

• • Solitary brain lesion or contralateral lung lesion as the only distant metastasis

  • Participation in another clinical study with an investigational product during the last 4 weeks
  • Patients with EGFR+, ALK+, ROS1+ disease or any other genetic alteration that would result in a TKI based first line treatment (i.e. first line treatment not being chemoimmuno- or immunotherapy)
  • Malignant pleural fluid, or ascites (malignant cells or clinical judgement) or excessive fluid hampering radiation according to protocol
  • Leptomeningeal disease
  • Pulmonary fibrosis making protocol stipulated treatment hazardous (low grade radiologic findings are allowed as assessed by the investigator)
  • Not deemed fit for standard first line systemic therapy
  • Second primary residual malignancy. Other malignancy diagnosed and treated > 2 years ago without relapse and deemed to have a low likelihood of relapse is allowed. (Carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin < 2 years are allowed, as is other low-grade malignancy with low likelihood of becoming metastatic or impact on survival e.g. low-grade prostate cancer not in need of treatment)
  • Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of systemic therapy
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Vastra Gotaland RegionOTHER_GOV

anders.vikstrom@regionostergotland.se

maria.planck@med.lu.se

karin.lindberg@ki.se

mikael.b.johansson@umu.se

georg.holgersson@akademiska.se

• Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

  NCT01282450

  CompletedInterventionalPhase 2Updated Jul 19, 2011
• Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC

  NCT04530708

  Unknown statusInterventionalNot ApplicableUpdated Aug 28, 2020
• First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

  NCT06840782

  RecruitingInterventionalPhase 3Updated Sep 15, 2025
• Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer

  NCT04495309

  CompletedInterventionalNot ApplicableUpdated Feb 27, 2026
• Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

  NCT04498767

  RecruitingInterventionalNot ApplicableUpdated Aug 26, 2024
• Metastases Directed Therapy for Oligometastatic Breast Cancer

  NCT06144346

  RecruitingInterventionalNot ApplicableUpdated Nov 22, 2023